Disclosures for "Exploring the Association of Disease Modifying Therapies for Multiple Sclerosis and BTK Inhibitors with Epilepsy"
-
Dr. Shirani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics.
-
Dr. Saez Calveras has nothing to disclose.
-
Dr. Antel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi, roche, biogen, wave,nervgen. The institution of Dr. Antel has received research support from Novartis canada bristol myers squib. Dr. Antel has a non-compensated relationship as a past president with ACTRIMS that is relevant to AAN interests or activities.
-
Mr. YAQUBI has nothing to disclose.
-
The institution of Dr. Moore has received research support from MS Canada.
-
Dr. Brewster has nothing to disclose.
-
Dr. Stuve has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurological Diseases. Dr. Stuve has received research support from US Department of Veterans Affairs. Dr. Stuve has received research support from National Multiple Sclerosis Society (US). Dr. Stuve has received research support from Merck KGaA.